Evidence map›Paper›PMID 34876813›Full record

ArticleInternational journal of nanomedicine2021

Assessment to the Antifungal Effects in vitro and the Ocular Pharmacokinetics of Solid-Lipid Nanoparticle in Rabbits.

Zhen Liang, Zhen Zhang, Jingjing Yang, Ping Lu, Tianyang Zhou, Jingguo Li, Junjie Zhang

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhen LiangHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Zhen ZhangHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Jingjing YangHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Ping LuHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Tianyang ZhouHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Jingguo LiHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.ORCID 0000-0002-0471-4540
Junjie ZhangHenan Eye Hospital, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFungal keratitis (FK) remains a severe sight-threatening disease, and case management is difficult due to ocular intrinsic barriers and drug shortages. Econazole (ECZ), a broad-spectrum antifungal agent, is limited in ocular applications due to the poor water solubility and strong irritant property.

methodsWe successfully prepared solid-lipid nanoparticle-based ECZ eye drops (E-SLNs) by microemulsion method, and the physicochemical properties of E-SLNs were investigated. Corneal permeability, antifungal ability against

resultsE-SLNs were a uniform and stable system which had an average particle size of 19 nm and a spherical morphology. E-SLNs also exhibited controlled release, enhanced antifungal activity without irritation. The pharmacokinetic analysis in vivo confirmed that E-SLNs showed an improved ocular bioavailability and the drug concentration in the cornea were above minimum inhibitory concentration (MIC) for 3 h after single administration.

conclusionThe E-SLNs colloid system is a promising therapeutic approach for fungal keratitis and could serve as a candidate strategy for other ocular diseases.

Indexed as

Antifungal AgentsNanoparticlesAnimalsCorneaDrug CarriersLipidsLiposomesParticle SizeRabbitsAntifungal AgentsDrug CarriersLipid NanoparticlesLipidsLiposomescorneal penetrationeconazolefungal keratitissolid-lipid nanoparticlestopical administration

Identifiers

PMID34876813
PMCPMC8643199
OpenAlexW3216017246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.